RxDoctor Payments Data

Linda le, MD

Vascular Surgery · Houston, TXNPI 1871841973

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (43.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 49 manufacturers reported payments, led by Silk Road Medical, Inc. at 25.6% of the total. Reporting peaked in 2024 at $17,301 and has fallen 75.5% since, to $4,233 in 2025.

$39,885in general payments, 2019–2025

Across 571 payments — averaging $69.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Silk Road Medical, Inc.$10K
  • W. L. Gore & Associates, Inc.$7K
  • Intuitive Surgical$6K
  • Baxter Healthcare$5K
  • Boston Scientific$2K
  • Inari Medical, Inc.$1K
  • plus $8K from 43 others
$26,235in research payments, 2019–2025

Across 3 payments — averaging $8745.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bard Peripheral Vascular, Inc.$26K

What the payments were for

  • Consulting fees$5,79315%
  • Speaking & faculty fees$7,70019%
  • Travel & lodging$3,4209%
  • Food & beverage$17,47244%
  • Education$5,50014%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,885 in reported general payments places this provider in the 85th percentile of 347 vascular surgery providers in Texas.

See all vascular surgery providers in Texas

Medicare billing

Part B allowed, 2024
$164,340
Medicare patients
386
Services billed
956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban13$9,092
EliquisApixaban12$7,970
ClopidogrelClopidogrel Bisulfate64$780
Cilostazol13$338
Gabapentin22$275
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$92
Tramadol Hcl36$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$424$9,09213 claims
PfizerEliquis$74$7,97012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 347 vascular surgery providers in Texas.

Other vascular surgery in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →